Alumis Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Alumis Inc. | ALMS - NASDAQ |
$16.00-$18.00 | $16.00 | $13.50 | 13.125 million | 6/28/2024 |
| Morgan Stanley, Leerink Partners, Cantor, Guggenheim Securities | ||||||
Co-Manager(s): | ||||||
| Health Care | ||||||
Filing(s): Terms Added 2024-06-24 Filed 2024-06-07 | ||||||
Alumis Inc. Quote & Chart - Click for current quote - ALMS
IPO Boutique aggregates information on public companies and private companies, such as "ALMS" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Alumis Inc. (adapted from Alumis Inc. prospectus):
Their mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
Their mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "ALMS" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.